카드리틱스, Inc.
GB ˙ LSE ˙ US14161W1053
US$0.64 ↓ -0.02 (-3.67%)
2026-06-03
주가
SecurityGB:0LEC / Cardlytics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership1,098,977 shares
Ownership 2.10%
BlackRock, Inc. ownership in 0LEC / Cardlytics, Inc.

2025-07-16 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,098,977 shares of Cardlytics, Inc. (GB:0LEC). This represents 2.1 percent ownership of the company. In their previous filing dated 2024-11-12 , BlackRock, Inc. had reported owning 3,137,388 shares, indicating a decrease of -64.97 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-07-16 2025-07-16 13G/A 3,137,388 1,098,977 -64.97 2.10 -66.67
2024-11-12 2024-11-12 13G/A 3,137,388 3,137,388 0.00 6.30 0.00
2024-10-24 2024-10-24 13G/A 3,137,388 6.30
2024-01-26 2024-01-26 13G/A 2,724,485 2,912,025 6.88 7.40 -9.76
2023-02-07 2023-02-07 13G/A 2,394,613 2,724,485 13.78 8.20 13.89
2022-02-03 2022-02-03 13G/A 2,048,867 2,394,613 16.87 7.20 -4.00
2021-02-02 2021-02-02 13G 2,048,867 7.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F CARDLYTICS COM 14161W105 990,629 24,406 2.53 1,040 -6.39 0.0000
2026-02-12 2025-12-31 13F CARDLYTICS COM 14161W105 966,223 -5,335 -0.55 1,111 -52.92 0.0000
2025-11-12 2025-09-30 13F CARDLYTICS COM 14161W105 971,558 -133,390 -12.07 2,361 29.88 0.0000
2025-08-12 2025-06-30 13F CARDLYTICS COM 14161W105 1,104,948 -2,041,729 -64.89 1,818 -68.27 0.0000
2025-05-02 2025-03-31 13F CARDLYTICS COM 14161W105 3,146,677 -82,571 -2.56 5,727 -52.20 0.0001
2025-02-07 2024-12-31 13F CARDLYTICS COM 14161W105 3,229,248 91,860 2.93 11,981 19.33 0.0002
2024-11-13 2024-09-30 13F CARDLYTICS COM 14161W105 3,137,388 -14,372 -0.46 10,040 -61.20 0.0002
2024-08-13 2024-06-30 13F CARDLYTICS COM 14161W105 3,151,760 281,005 9.79 25,876 -37.80 0.0006
2024-05-10 2024-03-31 13F CARDLYTICS COM 14161W105 2,870,755 -41,270 -1.42 41,597 55.10 0.0010
2024-02-13 2023-12-31 13F CARDLYTICS COM 14161W105 2,912,025 261,714 9.87 26,820 -38.67 0.0007
2023-11-13 2023-09-30 13F CARDLYTICS COM 14161W105 2,650,311 -206,202 -7.22 43,730 142.23 0.0013
2023-08-11 2023-06-30 13F CARDLYTICS COM 14161W105 2,856,513 269,375 10.41 18,053 105.54 0.0005
2023-05-12 2023-03-31 13F CARDLYTICS COM 14161W105 2,587,138 -137,347 -5.04 8,783 -44.22 0.0003
2023-02-13 2022-12-31 13F CARDLYTICS COM 14161W105 2,724,485 132,389 5.11 15,748 -35.37 0.0005
2022-11-14 2022-09-30 13F CARDLYTICS COM 14161W105 2,592,096 -31,154 -1.19 24,366 -58.37 0.0008
2022-08-12 2022-06-30 13F CARDLYTICS COM 14161W105 2,623,250 252,148 10.63 58,524 -55.11 0.0019
2022-05-12 2022-03-31 13F CARDLYTICS COM 14161W105 2,371,102 -23,511 -0.98 130,362 -17.63 0.0035
2022-02-10 2021-12-31 13F CARDLYTICS COM 14161W105 2,394,613 -74,980 -3.04 158,262 -23.65 0.0040
2021-11-09 2021-09-30 13F CARDLYTICS COM 14161W105 2,469,593 -41,702 -1.66 207,297 -34.97 0.0058
2021-08-11 2021-06-30 13F CARDLYTICS COM 14161W105 2,511,295 111,838 4.66 318,760 21.10 0.0089
2021-05-07 2021-03-31 13F CARDLYTICS COM 14161W105 2,399,457 350,590 17.11 263,221 -10.02 0.0077
2021-02-05 2020-12-31 13F CARDLYTICS COM 14161W105 2,048,867 83,096 4.23 292,517 110.86 0.0093
2020-11-06 2020-09-30 13F CARDLYTICS COM 14161W105 1,965,771 219,519 12.57 138,726 13.52 0.0051
2020-08-14 2020-06-30 13F CARDLYTICS COM 14161W105 1,746,252 551,881 46.21 122,203 192.67 0.0049
2020-05-01 2020-03-31 13F CARDLYTICS COM 14161W105 1,194,371 23,576 2.01 41,755 -43.27 0.0020
2020-02-13 2019-12-31 13F CARDLYTICS COM 14161W105 1,170,795 113,833 10.77 73,598 107.73 0.0028
2019-11-08 2019-09-30 13F CARDLYTICS COM 14161W105 1,056,962 153,343 16.97 35,430 50.92 0.0015
2019-08-22 2019-06-30 13F/A-1 CARDLYTICS COM 14161W105 903,619 438,215 94.16 23,476 205.00 0.0010
2019-08-13 2019-06-30 13F CARDLYTICS COM 14161W105 903,619 438,215 23,476
2019-05-09 2019-03-31 13F CARDLYTICS COM 14161W105 465,404 42,686 10.10 7,697 68.13 0.0003
2019-02-08 2018-12-31 13F CARDLYTICS COM 14161W105 422,718 1,610 0.38 4,578 -56.59 0.0002
2018-11-09 2018-09-30 13F CARDLYTICS COM 14161W105 421,108 68,208 19.33 10,545 37.32 0.0005
2018-08-09 2018-06-30 13F CARDLYTICS COM 14161W105 352,900 119,064 50.92 7,679 124.53 0.0004
2018-05-09 2018-03-31 13F CARDLYTICS COM 14161W105 233,836 233,836 3,420 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.